RecruitingPHASE1, PHASE2NCT06047379
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Studying Diffuse astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neonc Technologies, Inc.
- Principal Investigator
- Tom Chen, MD, PhDNeOnc Technologies
- Intervention
- NEO212 Oral Capsule(drug)
- Enrollment
- 134 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2027
Study locations (6)
- Precision NextGen Oncology, Beverly Hills, California, United States
- OPN Healthcare, Inc, Glendale, California, United States
- University of Southern California, Los Angeles, California, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
- Baylor, Scott and White Research Institute, Dallas, Texas, United States
- Northwest Medical Specialties, Tacoma, Washington, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06047379 on ClinicalTrials.govOther trials for Diffuse astrocytoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT04729959Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent GlioblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE4NCT03975829Pediatric Long-Term Follow-up and Rollover StudyNovartis Pharmaceuticals
- ACTIVE NOT RECRUITINGNANCT03739372Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade GliomaUniversity of California, San Francisco